Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents | Zendy

Philippe Généreux | Zendy; David R. Rutledge | Zendy; Tullio Palmerini | Zendy; Adriano Caixeta | Zendy; Elvin Kedhi | Zendy; James Hermiller | Zendy; Jin Wang | Zendy; Mitchell W. Krucoff | Zendy; Jennifer Jones-McMeans | Zendy; Krishnankutty Sudhir | Zendy; Charles A. Simonton | Zendy; Patrick W. Serruys | Zendy; Gregg W. Stone | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents

Author(s) -

Philippe Généreux,

David R. Rutledge,

Tullio Palmerini,

Adriano Caixeta,

Elvin Kedhi,

James Hermiller,

Jin Wang,

Mitchell W. Krucoff,

Jennifer Jones-McMeans,

Krishnankutty Sudhir,

Charles A. Simonton,

Patrick W. Serruys,

Gregg W. Stone

Publication year - 2015

Publication title -

circulation cardiovascular interventions

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.621

H-Index - 95

eISSN - 1941-7632

pISSN - 1941-7640

DOI - 10.1161/circinterventions.114.001362

Subject(s) - discontinuation , medicine , hazard ratio , confidence interval , stent , everolimus , surgery

Whether premature dual antiplatelet therapy (DAPT) interruption is safe in patients receiving cobalt chromium everolimus-eluting stents remains controversial. We sought to examine the relationship between DAPT discontinuation and stent thrombosis (ST) after cobalt chromium everolimus-eluting stents.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research